In this free webinar, learn the current view on trends, challenges and strategies in drug product development and manufacturing. The featured speakers will share insights into highly potent active pharmaceutical ingredients (HPAPI) handling and ensuring utmost safety and keeping flexibility at the same time. Attendees will learn how low-dosing technology can be advantageous for current drug product development and manufacturing challenges.
TORONTO, Oct. 2, 2023 /PRNewswire-PRWeb/ -- The landscape of drug development is constantly evolving, presenting pharmaceutical companies with unique challenges that demand innovative solutions. Among others, critical areas that require special attention are highly potent active pharmaceutical ingredients (HPAPI) and handling of micro-dosed APIs at the same time. The webinar explores the challenges, and the measures drug developers and manufacturers must adopt to effectively handle HPAPIs, as well as solid dosage form technologies that allow for handling low-dosed APIs.
HPAPI handling stands out as a paramount concern in the current research and development (R&D) pipeline, accounting for a significant 50 percent of the projects. These potent APIs often exhibit remarkable efficacy even at extremely low doses. Consequently, drug product development companies must adopt a comprehensive approach to address the complexities that arise from HPAPI handling. This holistic concept revolves around three pillars: production equipment, processes and people.
Implementing specific concepts for shared facilities and establishing highly flexible setups become crucial factors for the fast and efficient development of drug products. These tailored approaches allow for quicker adaptation to the unique requirements of each HPAPI, ensuring safety, and maintaining high productivity levels.
Drug developers must be proactive in their approach to adapt to the current challenges in the R&D pipeline. By effectively handling HPAPIs, devising targeted therapy solutions and employing advanced formulation technologies, they can pave the way for successful drug development in the future.
Join this webinar to get insights into the challenges and strategies in drug product development and manufacturing and the safe and flexible handling of HPAPIs.
Join experts from Aenova Group, Florent Bordet, Chief Scientific Officer (CSO); Klaus Pollinger, PhD, Head of Manufacturing Science & Technology; and Martina Breuer, PhD, Head of Operations / QP, for the live webinar on Tuesday, October 10, 2023, at 11am EDT (4pm GMT/UK).
For more information, or to register for this event, visit Drug Product Development: Challenges and Strategies for High-Potent and Low-Dosed Products.
ABOUT AENOVA GROUP
The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a one-stop store, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health: solid, semi-solid and liquid, sterile and non-sterile, high and low dose, OEB 1 to 5 (Occupational Exposure Band). Approximately 4,000 employees at 14 sites in Europe and the U.S. contribute to the company's success. For more information, visit http://www.aenova-group.com.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com
SOURCE Xtalks
Share this article